Theratechnologies Obtains US Patent for Improving Cognitive Function with Tesamorelin in Patients Suffering from MCI
(firmenpresse) - MONTREAL, CANADA -- (Marketwired) -- 07/11/13 -- Theratechnologies Inc. (TSX: TH) today announced that the US Patent and Trademark Office (USPTO) has issued Patent No. 8,481,489 entitled "GH Secretagogues and Uses Thereof" covering a method of improving cognitive function in a subject suffering from mild cognitive impairment (MCI) through the administration of tesamorelin. The patent will expire in 2024.
"We are glad the USPTO delivered this patent as it enlarges the protection of tesamorelin for use in a potential therapeutic area" stated Luc Tanguay, President and Chief Executive Officer of Theratechnologies.
About Theratechnologies
Theratechnologies (TSX: TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on the SEC's website at .
Contacts:
Denis Boucher
NATIONAL Public Relations
514-843-2393
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.07.2013 - 11:30 Uhr
Sprache: Deutsch
News-ID 277491
Anzahl Zeichen: 0
contact information:
Town:
MONTREAL, CANADA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Theratechnologies Obtains US Patent for Improving Cognitive Function with Tesamorelin in Patients Suffering from MCI"
steht unter der journalistisch-redaktionellen Verantwortung von
Theratechnologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
